HPB Surgery

Clinical Study

Preoperative Gadoxetic Acid-Enhanced MRI and Simultaneous Treatment of Early Hepatocellular Carcinoma Prolonged Recurrence-Free Survival of Progressed Hepatocellular Carcinoma Patients after Hepatic Resection

Table 1

Comparison of background factors between the EOB-MRI (+) and EOB-MRI (−) groups.
FactorEOB-MRI (+)EOB-MRI (−) value
( )( )
Sex (male/female) 0.85
Age (years)*68 (16–86)69 (35–85)0.71
History of blood transfusions (present/absent) 0.46
History of schistosomiasis japonica (present/absent) 0.50
Alcoholism (present/absent) >0.999
Smoking (present/absent) 0.73
Diabetes mellitus (present/absent) 0.08
Esophageal varix (present/absent) 0.54
Albumin (g/dL)*4.0 (3.1–4.8)3.9 (3.2–4.7)0.23
Total Bilirubin (mg/dL)0.7 (0.3–1.6)0.7 (0.2–1.4)0.91
Alanine aminotransferase (IU/L)*37 (9–168)37 (10–286)0.73
Platelets (×104/ L)*12.4 (3.2–35.6)13.7 (5.7–32.8)0.12
Indocyanine green retention rate at 15 minutes (%)*15.3 (5.4–30.6)12.6 (5.5–38.0)0.35
Prothrombin time (%)*83.2 (54.6–113.5)78.7 (61.7–100)0.13
Child-Pugh score (A/B) 0.23
Alpha-fetoprotein (ng/mL)*10.7 (9–17521)14.3 (1.7–128900)0.19
Alpha-fetoprotein L3 (%)*1.2 (0–80.4)2.1 (0–77.7)0.33
Des- -carboxy prothrombin (mAU/mL)*29.0 (9–17521)57.0 (12–30805)0.02
Hepatitis B surface antigen (positive/negative) 0.84
Hepatitis C antibodies (positive/negative) >0.999
Tumor size in greatest dimension (cm)*2.6 (0.9–10.7)3.0 (1.0–9.0)0.14
Number of tumors (solitary/multiple) 0.13
Fibrous capsule formation (present/absent) 0.12
Vascular invasion (present/absent) 0.32
Pathological diagnosis (well or moderate/poor) 0.84
Liver cirrhosis (present/absent) 0.87
AJCC Stage (I/II or III) 0.24
Hepatic resection (major/minor) 0.73
Treatment for eHCC 0.04
Median (range).